Clinical trial

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment

Name

Maha Nabil

Description

Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse of the immune privilege of the hair follicle caused by immunological mechanism. Multiple genetic, environment factors and psychological stress contribute to the pathogenesis of Alopecia Areata . Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as Janus kinase inhibitors, biologics and several small molecular agents. In addition, modern therapies for AA, including antihistamines, platelet-rich plasma injection

Trial arms

Trial start

2024-02-01

Estimated PCD

2024-04-20

Trial end

2024-05-01

Status

Recruiting

Phase

Early phase I

Treatment

Latanoprost

Comparing between Erbium YAG laser assisted drug delivery of latanoprost versus transepidermal latanoprost delivery by microneedling in alopecia areata treatment for all participants.

Arms:

Fractional Erbium laser Technique (Group A), Micro needling Technique (Group B)

Other names:

fractional Erbium- YAG laser

Size

Primary endpoint

fractional Erbium YAG laser

from baseline to 3 months after the fractional Erbium YAG laser treatment day.

Eligibility criteria

Inclusion Criteria: * Patients of both sexes with localized stable alopecia areata of the scalp of 3 months duration at least. Exclusion Criteria: 1. Acute or chronic infections. 2. Pregnant or lactating women. 3. Scarring alopecia. 4. Alopecia totalis , Alopecia universalis and ophiasis. 5. Autoimmune dermatological diseases.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 70, 'type': 'ESTIMATED'}}

Updated at

2024-04-16

1 organization

1 product

1 indication

Product

Latanoprost

Indication

Alopecia Areata

Organization

Egymedicalpedia